ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

onametostat

Its studies are mostly in Leukemia, Myeloid, Acute · Lymphoma, Non-Hodgkin, led by Johnson & Johnson.

Furthest: phase 1, since Jun 20, 20182 company-led studies, 1 open or runningNext primary completion: Jan 19, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson21 open or runningphase 1since Jun 20, 2018Jun 20, 2018Jan 19, 2028phase 1 · NCT06788509

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 20, 2018First study: phase 1 study in NeoplasmsFirst studyNCT03573310 · 114 enrolled · United States, Canada, Germany and more
  2. Jun 9, 2020Named onametostatINNProposed as its International Nonproprietary Name in WHO's List 123 · before, JNJ-64619178
  3. Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more

Ahead

  1. Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509

TargetBeta

PRMT5 →read by rule
“An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), ”NCIt, by rule

Other programs on PRMT5

ProgramCompanyFurthest phaseStudies
navlimetostatBristol-Myers Squibbphase 310
PRMT5 Inhibitor AZD3470AstraZenecaphase 22
JBI-778rulejubilant-therapeutics-india-limitedphase 22
PRMT5 Inhibitor TNG456ruletango-therapeutics-incphase 21
PRMT5 Inhibitor BAY 3713372ruleBayerphase 21
PRMT5 Inhibitor SH3765ruleNanjing Sanhome Pharmaceuticalphase 12
PRMT5 Inhibitor BGB-58067ruleBeOne Medicinesphase 12
PRMT5 Inhibitor IDE892ruleideaya-biosciencesphase 11
PEP08rulepharmaenginephase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more1By invitationJan 19, 2028120
NCT03573310Neoplasms · United States, Canada, Germany and more1CompletedSep 25, 2025114

How it is read

Names in the registry

  • “JNJ-64619178”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
onametostat (Johnson & Johnson): development program | ClinicalTrials.gg